NCT00394901 - A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia | Biotech Hunter

Enrollment

372

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Neuralgia, Postherpetic

Interventions

DRUG

Placebo

placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).

DRUG

Pregabalin

Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).

DRUG

Pregabalin

Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).

DRUG

Pregabalin

Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).

Trial Locations (39)

Unknown

Pfizer Investigational Site, Nagoya

Pfizer Investigational Site, Ichikawa

Pfizer Investigational Site, Urayasu

Pfizer Investigational Site, Kasuga

Pfizer Investigational Site, Kasuya-gun

Pfizer Investigational Site, Maebaru-chūō

Pfizer Investigational Site, Maebashi

Pfizer Investigational Site, Takasaki

Pfizer Investigational Site, Asahikawa

Pfizer Investigational Site, Sapporo

Pfizer Investigational Site, Akashi

Pfizer Investigational Site, Amagasaki

Pfizer Investigational Site, Himeji

Pfizer Investigational Site, Kobe

Pfizer Investigational Site, Nishinomiya

Pfizer Investigational Site, Tsuchiura

Pfizer Investigational Site, Sagamihara

Pfizer Investigational Site, Yokohama

Pfizer Investigational Site, Sendai

Pfizer Investigational Site, Beppu

Pfizer Investigational Site, Kishiwada

Pfizer Investigational Site, Takatsuki

Pfizer Investigational Site, Kawaguchi

Pfizer Investigational Site, Kitamoto

Pfizer Investigational Site, Tokorozawa

Pfizer Investigational Site, Adachi-ku

Pfizer Investigational Site, Arakawa-ku

Pfizer Investigational Site, Bunkyo-ku

Pfizer Investigational Site, Edogawa-ku

Pfizer Investigational Site, Mitaka

Pfizer Investigational Site, Nakano-ku

Pfizer Investigational Site, Shinagawa-ku

Pfizer Investigational Site, Shinjuku-ku

Pfizer Investigational Site, Suginami-ku

Pfizer Investigational Site, Toshima-ku

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Fukushima

Pfizer Investigational Site, Osaka

Pfizer Investigational Site, Saitama

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY